Compare Allegion PLC (ALLE) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Allegion PLC vs Medpace Holdings Inc — how do they compare? Allegion PLC trades at $136.63 (market cap $11.74B), while Medpace Holdings Inc trades at $538.23 (market cap $15.37B). The key difference: Medpace Holdings Inc is the larger of the two by market cap, and Allegion PLC pays a 1.55% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| ALLE | MEDP | |
|---|---|---|
Market Cap | $11.74B | $15.37B |
Sector | Industrials | Technology |
52-Week High | $179.77 | $620.59 |
52-Week Low | $125.65 | $308.88 |
Enterprise Value | $13.46B | $14.84B |
Dividend Yield | 1.55% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALLE trades at $136.63, up 1.15% today, with a bearish technical signal but strong profitability metrics including a 15.24% net income margin and 34.18% ROE. Recent earnings missed estimates in Q1 2026, but revenue growth remains steady, reaching $4.07B in 2025. The company continues innovation with new product launches like the Schlage Sense Pro smart deadbolt, supporting long-term growth in security solutions.
The stock presents a mixed outlook: analyst consensus is a $152.50 price target with a 'Hold' bias, offering potential upside, but technical weakness and recent earnings misses pose near-term risks. Investors should weigh strong fundamentals against execution challenges and macroeconomic pressures affecting margins.
MEDP trades at $538.23, up 0.51% with a bullish technical signal and strong fundamentals. The stock shows robust profitability with 17.19% net margins and 77.25% ROE, though valuations appear elevated with a P/E of 33.87. Recent earnings consistently beat expectations, and 2026 projections indicate revenue growth to $2.7B. Technical analysis shows support at $527 and resistance at $543, with the current price near pivot point $535.
MEDP presents growth potential from strong CRO demand and earnings momentum, but faces risks from class action lawsuits and elevated valuation multiples. Analyst consensus is cautious with 74% hold ratings and a $479 price target below current levels. The stock's outlook depends on maintaining backlog quality amid rising cancellations and AI investment delays.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Allegion PLC
Allegion is a global security products company with a portfolio of leading brands, such as Schlage, von Duprin, and LCN. The Ireland-domiciled company was created via a spinoff transaction from Ingersoll-Rand in December 2013. In fiscal 2021, Allegion generated 68% of sales in the United States. The company mainly competes with Swedish-based Assa Abloy AB and Switzerland-based Dormakaba.
Read more on ALLE →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
